Biocure Technology

Biocure Technology Dividend per Share

Dividend per Share of Biocure Technology (CURE.X.CN) as of Nov 16, 2026.

Dividend per Share

0.00CAD

Last updated:

Dividend per Share of Biocure Technology is 2024 0.00 CAD. Dividend per Share of Biocure Technology was 2023 0.00 CAD. It decreases by % lower compared to the previous year.

The Biocure Technology Dividend per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend per Share
Date
Dividend per Share
Jan 1, 2017
0.00 CAD
Jan 1, 2018
0.00 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
0.00 CAD
Jan 1, 2021
0.00 CAD
Jan 1, 2022
0.00 CAD
Jan 1, 2023
0.00 CAD
Jan 1, 2024
0.00 CAD
The Biocure Technology Dividend per Share history
YEARDividend per ShareYoY
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—
0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocure Technology Stock analysis

What does Biocure Technology do? Biocure Technology Inc develops and commercializes biosimilar products, focusing on biopharmaceutical technologies for recombinant and ranibizumab applications. The company's products include Interferon Beta, Ranibizumab, and PEG-Filgrastim, targeting chronic lymphocytic leukemia and solid tumor cancers through its own CAR T-cell therapy. Biocure's scientists specialize in developing these therapies, which are sold to healthcare providers and pharmaceutical companies seeking cost-effective alternatives to branded biologics. The firm's commercialization efforts center on biosimilar technologies for cancer treatment, leveraging its expertise in CAR T-cell therapy development. The company generates revenue through the sale of its biosimilar products, including Interferon Beta, Ranibizumab, and PEG-Filgrastim, to healthcare institutions and pharmaceutical partners. These products are marketed as cost-efficient alternatives for cancer treatment, with a focus on chronic lymphocytic leukemia and solid tumor applications. Biocure's development of CAR T-cell therapy for targeted cancer treatment represents a key segment of its revenue stream, alongside its broader biosimilar technology portfolio. Healthcare providers and pharmaceutical companies purchasing these products form the primary customer base for Biocure's commercialized therapies. Biocure Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocure Technology stock

On Eulerpool you can find the complete historical development of Dividend per Share Biocure Technology since 2006 – with annual values, charts, and detailed analysis.

Dividend per share is the total dividend payment divided by shares outstanding. It shows how much cash each share receives in dividends.

Dividend per Share's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend per Share's Biocure Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Biocure Technology

All Key Metrics — Biocure Technology